Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (POE14-01)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Phoenix Children's Hospital
Pediatric Oncology Experimental Therapeutics Investigators' Consortium
Information provided by (Responsible Party):
Jessica Boklan, MD, Phoenix Children's Hospital Identifier:
First received: July 21, 2015
Last updated: April 7, 2016
Last verified: April 2016

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia.

Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved for the disease being treated in this study. Since carfilzomib has not yet been used in this setting to treat this condition, the investigators must first find the best dose to give. The investigators are looking for the highest dose of carfilzomib that can be given safely. Therefore, not all children taking part in this study will receive the same dose of the study drug in the first part of the trial.

Condition Intervention Phase
Relapsed Solid Tumors
Refractory Solid Tumors
Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Etoposide
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias

Resource links provided by NLM:

Further study details as provided by Phoenix Children's Hospital:

Primary Outcome Measures:
  • To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors [ Time Frame: Screening to 2 years ]

Secondary Outcome Measures:
  • Collect information on all adverse events that occur with this regimen [ Time Frame: Screening to 2 years ]
  • Determine patient response rate (CR, PR, SD, PD) with this regimen [ Time Frame: Screening to 2 years ]
  • Circulating plasma proteasome (cProt) levels post treatment [ Time Frame: 2 years ]
  • Levels of proteasome activity [ Time Frame: 2 years ]
  • Inhibition of proteasome activity by carfilzomib [ Time Frame: 2 years ]
  • Proteasome inhibition in patient PBMCs before and during treatment by determination of the level of protein ubiquitination. [ Time Frame: 2 years ]
  • In vitro sensitivity of patient leukemias and solid tumors to carfilzomib alone and in combination with study chemotherapeutic agents [ Time Frame: Screening to 2 years ]
  • Alterations of proteasome activity in tumor samples [ Time Frame: 2 years ]
  • Expression of actionable mutations [ Time Frame: 2 years ]

Estimated Enrollment: 50
Study Start Date: July 2015
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Carfilzomib
Carfilzomib in combination with cyclophosphamide and etoposide
Drug: Carfilzomib
Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
Drug: Cyclophosphamide Drug: Etoposide

Detailed Description:

The purpose of this study is to find out what effects, good and/or bad, treatment with a new combination of drugs, cyclophosphamide, etoposide, and carfilzomib has on cancer.

In part 1 of the trial, small groups of children will be enrolled in steps. The first group will be given a certain dose of carfilzomib. If these children do not have side effects which are too bad, the next small group of children enrolled will receive a higher dose. This increase in doses with groups of people will continue until we find the highest dose of the drug that can be given without causing severe or unmanageable side effects.

Part 2 of this study will enroll additional patients at the highest tolerable dose found in Part 1 in order to get more information on side effects and make sure the dose is tolerable.


Ages Eligible for Study:   6 Months to 29 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have either of the following:

    1. Relapsed/refractory leukemia in 2nd or greater relapse or who have failed at least one re-induction attempt after relapse or for refractory disease. Patients must meet the WHO classification with ≥ 5% blasts in the bone marrow or must have definitive extramedullary disease (e.g. chloromas, skin lesions). Patients may have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS disease.


    2. Relapsed/refractory non-CNS solid tumor that has not responded or has relapsed and for which no standard treatment is available. Patients may not have primary CNS tumors or CNS metastases. Lymphoma patients are permitted. Patients do not need to have measurable disease.
  2. Age 6 months - 29.99 years at enrollment
  3. Life expectancy ≥ 3 months
  4. Lansky or Karnofsky ≥50
  5. Prior therapy

    1. Patient must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, radiotherapy, or surgery prior to study entry.
    2. Myelosuppressive therapy- At least 14 days must have elapsed since the administration of previous therapy. Six weeks must have elapsed from the administration of nitrosureas or mitomycin C. For patients with ALL on maintenance therapy, they may be eligible if 7 days have elapsed and they are recovered from the toxic effects of the chemotherapy. This restriction does not include intrathecal chemotherapy, which is permitted.
    3. Biologic agents- At least 14 days must have elapsed since the completion of therapy with a biologic agent such as a monoclonal antibody. Seven days must have elapsed since the last dose of retinoids
    4. Radiation therapy - At least 14 days must have elapsed for local XRT. At least 90 days must have elapsed if prior radiation to ≥50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI.
    5. Hematopoietic growth factors- At least 7 days must have elapsed since the last dose of G-CSF or GM-CSF. At least 14 days must have elapsed since last dose of pegfilgrastim (Neulasta®).
  6. Patient must be ≥ 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppression
  7. Organ function:

    1. Either a serum creatinine ≤ ULN for age, or calculated or measured GFR ≥ 70 mL/min/1.73 m2
    2. Total bilirubin ≤ 1.5 x ULN for age, direct bilirubin ≤ ULN for age
    3. AST and ALT ≤ 3 x ULN for age unless elevation can be clearly attributed to liver leukemia or metastases
    4. ECHO shortening fraction ≥ 27%
    5. Pulse Oximetry measurement ≥ 95% saturation without supplemental oxygen
  8. Bone marrow function:

    1. Hgb ≥10 g/dL - can be transfused
    2. Plts ≥ 75,000 - cannot be transfused (must be ≥ 7 days from last plt transfusion)
    3. ANC ≥ 750 - cannot be transfused (must be ≥ 72 hours from last neutrophil infusion)

    However, the plt and ANC requirements can be waived if low counts thought to be secondary to leukemia or tumor bone marrow infiltration

  9. Reproductive function:

    1. Female patients of childbearing potential must have a negative serum pregnancy test confirmed within 7 days prior to enrollment
    2. Female patients with infants must agree not to breastfeed their infants while on the study
    3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatment
  10. Written informed consent

Exclusion Criteria:

  1. Prior treatment with carfilzomib
  2. Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
  3. Down syndrome
  4. Fanconi Anemia or other underlying bone marrow failure syndrome
  5. Pregnant or lactating females
  6. Known history of Hepatitis B or C or HIV
  7. Patient with any significant concurrent illness
  8. Patient with uncontrolled systemic fungal, bacterial, viral or other infection with ongoing signs/symptoms despite appropriate treatment
  9. Patient with illness, psychiatric disorder or social issue that could compromise patient safety or compliance with the protocol treatment or procedures, or interfere with the consent, study participation, follow-up, or interpretation of study results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02512926

Contact: Jessica Boklan, MD 602-933-0920
Contact: Aru Narendran, MD, PhD 403-210-6418

United States, Arizona
Phoenix Children's Hospital Recruiting
Phoenix, Arizona, United States, 85016
Contact: Lauree Deublein    602-933-5004   
Contact: Sam Chimienti    602-933-0188   
Sponsors and Collaborators
Phoenix Children's Hospital
Pediatric Oncology Experimental Therapeutics Investigators' Consortium
  More Information

Responsible Party: Jessica Boklan, MD, Principal Investigator, Phoenix Children's Hospital Identifier: NCT02512926     History of Changes
Other Study ID Numbers: POE14-01
Study First Received: July 21, 2015
Last Updated: April 7, 2016

Keywords provided by Phoenix Children's Hospital:
Solid Tumors

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Etoposide phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on April 21, 2017